Previous 10 | Next 10 |
CORAL GABLES, Fla., May 19, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare dise...
Image source: The Motley Fool. Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) Q1 2021 Earnings Call May 11, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Catalyst Pharmaceuticals Inc (CPRX) Q1 2021 Earnings Call Tran...
Catalyst Pharmaceuticals, Inc. (CPRX) Q1 2021 Earnings Conference Call May 11, 2021 8:30 AM ET Company Participants Alicia Grande – Vice President, Chief Financial Officer and Treasurer Patrick McEnany – Chairman and Chief Executive Officer Jeffrey Del Carmen – Chief Comm...
-Firdapse® Q1 2021 Net Revenues of $30.2 Million -First Quarter 2021 GAAP Net Income of $7.7 Million; Non-GAAP Net Income of $11.6 Million -Recently Received Orphan Drug Designation for Firdapse® in Japan -$143.3 Million in Cash and Investments and no Fun...
For under-the-radar companies, it's important to make sure any positive news finds its way to the eyes or ears of investors. The first quarter of 2021 is evidence of that for one small player dedicated to treating rare diseases in the pharmaceutical market. Catalyst Pharmaceuticals (N...
CORAL GABLES, Fla., May 03, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare dis...
It has been one year since the markets bottomed in March of 2020 due to COVID. Markets have rebounded beyond most investors’ expectations, with growth and tech stealing much of the spotlight. The “rotation into value” narrative has recently gained some tractio...
Supernus Pharmaceuticals (NASDAQ: SUPN) , Corcept Therapeutics (NASDAQ: CORT) , and Catalyst Pharmaceuticals (NASDAQ: CPRX) don't have much in common. But it does so happen that they're all in the healthcare space, trade for less than $26 per share, and have the pote...
Should You Be Watching These 4 Penny Stocks This Week? March has been an interesting month for penny stocks, to say the least. While most days have been bullish for penny stock investors, underlying factors have pushed some days to be bearish. In the market right now, there are several ...
Some Of The Best Penny Stocks To Watch Early This Week This week has started stronger than the last & we have plenty of trending penny stocks to watch as a result. Last week the markets sold off, with tech continuing its move lower. What’s more, over the weekend, new virus da...
News, Short Squeeze, Breakout and More Instantly...
Catalyst Pharmaceuticals Inc. Company Name:
CPRX Stock Symbol:
NASDAQ Market:
Catalyst Pharmaceuticals Inc. Website:
CORAL GABLES, Fla., July 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-...
2024-06-20 17:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-03 11:30:04 ET H.C. Wainwright analyst issues UNDERPERFORM recommendation for CPRX on June 3, 2024 09:00AM ET. The previous analyst recommendation was Underperform. CPRX was trading at $16.38 at issue of the analyst recommendation. The overall analyst consensus :...